Roger Schibli

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 32

Top Venues

Cancers

Pharmaceutics

EJNMMI research

Journal of labelled compounds & radiopharmaceuticals

ETH-Bereich Hochschulen

This page only lists publications with an associated author ORCID identifier.

Affiliation History

ETH-Bereich Hochschulen Jun 01 2004

Switzerland

Lab Head/Full Professor :: Chemistry and Applied Biosciences

Paul Scherrer Institut Oct 01 1998

Switzerland

Lab Head/Full Professor :: BIO

Publications

Rahel H Wallimann, Heloïse Hensinger, Cristina Müller, Roger Schibli, Rainer Kneuer, Patrick Schindler
Liquid Chromatography ICP-MS to Assess the Stability of 175 Lu- and nat Ga-Based Tumor-Targeting Agents towards the Development of 177 Lu- and 68 Ga-Labeled Radiopharmaceuticals. Pharmaceutics 16 (3) (2024)
Rahel H Wallimann, Heloïse Hensinger, Cristina Müller, Roger Schibli, Rainer Kneuer, Patrick Schindler
Liquid Chromatography ICP-MS to Assess the Stability of 175 Lu- and nat Ga-Based Tumor-Targeting Agents towards the Development of 177 Lu- and 68 Ga-Labeled Radiopharmaceuticals. Pharmaceutics 16 (3) (2024)
Christian Vaccarin, Ana Katrina Mapanao, Luisa M Deberle, Anna E Becker, Francesca Borgna, Giovanni Marzaro, Roger Schibli, Cristina Müller
Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder. Cancers 16 (7) (2024)
Belinda Trachsel, Stefan Imobersteg, Giulia Valpreda, Gad Singer, Regula Grabherr, Mark Ormos, Irene Andrea Burger, Rahel A Kubik-Huch, Roger Schibli, Viola Vogel, Martin P Béhé
Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI research 14 (1) (2024)
Rahel H Wallimann, Heloïse Hensinger, Cristina Müller, Roger Schibli, Rainer Kneuer, Patrick Schindler
Liquid Chromatography ICP-MS to Assess the Stability of 175 Lu- and nat Ga-Based Tumor-Targeting Agents towards the Development of 177 Lu- and 68 Ga-Labeled Radiopharmaceuticals. Pharmaceutics 16 (3) (2024)
Christian Vaccarin, Ana Katrina Mapanao, Luisa M Deberle, Anna E Becker, Francesca Borgna, Giovanni Marzaro, Roger Schibli, Cristina Müller
Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder. Cancers 16 (7) (2024)
Belinda Trachsel, Stefan Imobersteg, Giulia Valpreda, Gad Singer, Regula Grabherr, Mark Ormos, Irene Andrea Burger, Rahel A Kubik-Huch, Roger Schibli, Viola Vogel, Martin P Béhé
Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI research 14 (1) (2024)
Christian Vaccarin, Ana Katrina Mapanao, Luisa M Deberle, Anna E Becker, Francesca Borgna, Giovanni Marzaro, Roger Schibli, Cristina Müller
Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder. Cancers 16 (7) (2024)
Belinda Trachsel, Stefan Imobersteg, Giulia Valpreda, Gad Singer, Regula Grabherr, Mark Ormos, Irene Andrea Burger, Rahel A Kubik-Huch, Roger Schibli, Viola Vogel, Martin P Béhé
Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI research 14 (1) (2024)
Sarah D Busslinger, Anna E Becker, Christian Vaccarin, Luisa M Deberle, Marie-Luise Renz, Viola Groehn, Roger Schibli, Cristina Müller
Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates. Cancers 15 (17) (2023)
Rahel H Wallimann, Patrick Schindler, Heloïse Hensinger, Viviane J Tschan, Sarah D Busslinger, Rainer Kneuer, Cristina Müller, Roger Schibli
Inductively Coupled Plasma Mass Spectrometry─A Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals. Molecular pharmaceutics (2023)
Sarah D Busslinger, Viviane J Tschan, Olivia K Richard, Zeynep Talip, Roger Schibli, Cristina Müller
[ 225 Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [ 225 Ac]Ac-PSMA-617. Cancers 14 (22) (2022)
Michal Grzmil, Fabius Wiesmann, Roger Schibli, Martin P Béhé
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer. Cancers 15 (1) (2022)
Michal Grzmil, Fabius Wiesmann, Roger Schibli, Martin P Béhé
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer. Cancers 15 (1) (2022)
Michal Grzmil, Fabius Wiesmann, Roger Schibli, Martin P Béhé
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer. Cancers 15 (1) (2022)
Nathalie M Grob, Roger Schibli, Martin P Béhé, Thomas L Mindt
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin 177Lu-PP-F11N. Cancers 13 (11) (2021)
Caitlin V M L Jie, Valerie Treyer, Roger Schibli, Linjing Mu
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland) 14 (2) (2021)
Francesca Borgna, Patrick Barritt, Pascal V Grundler, Zeynep Talip, Susan Cohrs, Jan Rijn Zeevaart, Ulli Koester, Roger Schibli, Nicholas P van der Meulen, Cristina Müller
Simultaneous Visualization of 161Tb- and 177Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging. Pharmaceutics 13 (4) (2021)
Michal Grzmil, Stefan Imobersteg, Alain Blanc, Savas Deniz Soysal, Roger Schibli, Martin P Béhé
Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [ 177 Lu]Lu-PP-F11N. Pharmaceutics 13 (12) (2021)
Nicholas P van der Meulen, Roger Hasler, Alain Blanc, Renata Farkas, Martina Benešová, Zeynep Talip, Cristina Müller, Roger Schibli
Implementation of a new separation method to produce qualitatively improved 64 Cu. Journal of labelled compounds & radiopharmaceuticals 62 (8) (2020)
Stefanie Dobitz, Patrick Wilhelm, Nina Romantini, Martina De Foresta, Cornelia Walther, Andreas Ritler, Roger Schibli, Philipp Berger, Xavier Deupi, Martin P Béhé, Helma Wennemers
Distance-Dependent Cellular Uptake of Oligoproline-Based Homobivalent Ligands Targeting GPCRs-An Experimental and Computational Analysis. Bioconjugate chemistry 31 (10) (2020)
Yingfang He, Linjing Mu, Simon M Ametamey, Roger Schibli
Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes. Journal of labelled compounds & radiopharmaceuticals 62 (8) (2020)
Cristina Müller, Roger Schibli, Britta Maurer
Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients at Risk? Pharmaceuticals (Basel, Switzerland) 13 (9) (2020)
Linjing Mu, Stefanie D Krämer, Geoffrey I Warnock, Ahmed Haider, Susan Bengs, Giovanni Cartolano, Dominic S Bräm, Claudia Keller, Roger Schibli, Simon M Ametamey, Philipp A Kaufmann, Christian Loewe
[11C]mHED PET follows a two-tissue compartment model in mouse myocardium with norepinephrine transporter (NET)-dependent uptake, while [18F]LMI1195 uptake is NET-independent. EJNMMI research 10 (1) (2020)
Klaudia Siwowska, Patrycja Guzik, Katharina A Domnanich, Josep Maria Monné Rodríguez, Peter Bernhardt, Bernard Ponsard, Roger Hasler, Francesca Borgna, Roger Schibli, Ulli Koester, Nicholas P van der Meulen, Cristina Müller
Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. Pharmaceutics 11 (8) (2019)
Cristina Müller, Maria De Prado Leal, Marco D Dominietto, Christoph A Umbricht, Sairos Safai, Rosalind L Perrin, Martina Egloff, Peter Bernhardt, Nicholas P van der Meulen, Damien C Weber, Roger Schibli, Antony J Lomax
Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. Pharmaceutics 11 (9) (2019)
Marc Pretze, Nick P van der Meulen, Carmen Wängler, Roger Schibli, Björn Wängler
Targeted 64 Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging. Journal of labelled compounds & radiopharmaceuticals 62 (8) (2019)
Adrienne Müller Herde, Silvan D Boss, Yingfang He, Roger Schibli, Linjing Mu, Simon M Ametamey
Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain. Pharmaceuticals (Basel, Switzerland) 11 (3) (2018)
Cristina Müller, Patrycja Guzik, Klaudia Siwowska, Susan Cohrs, Raffaella M Schmid, Roger Schibli
Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates. Molecules (Basel, Switzerland) 23 (6) (2018)
Richard P Baum, Aviral Singh, Martina Benešová, Christiaan Vermeulen, Silvano Gnesin, Ulli Koester, Karl Johnston, Dirk Müller, Stefan Senftleben, Harshad V Kulkarni, Andreas Türler, Roger Schibli, John O Prior, Nicholas P van der Meulen, Cristina Müller
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. Dalton transactions (Cambridge, England : 2003) 46 (42) (2018)
Marco F Taddio, Linjing Mu, Claudia Keller, Roger Schibli, Stefanie D Krämer
Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice. Contrast media & molecular imaging 2018 (2018)
Philipp R Spycher, Christian A Amann, Jöri E Wehrmüller, David R Hurwitz, Olivier Kreis, Daniel Messmer, Andreas Ritler, Andreas Küchler, Alain Blanc, Martin Béhé, Peter Walde, Roger Schibli
Dual, Site-Specific Modification of Antibodies by Using Solid-Phase Immobilized Microbial Transglutaminase. Chembiochem : a European journal of chemical biology 18 (19) (2017)

Roger Schibli.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Roger Schibli